SCHEMBL684000

SCHEMBL684000

Cn1c(=O)c2c(ncn2CC(O)CN2CCN(Cc3ccccc3)CC2)n(C)c1=O

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.65
RXFP1 Q9HBX9 5/20 0.65
ADORA2B P29275 1/20 0.65
LMNA P02545 3/20 0.60
POLB P06746 2/20 0.60
ALDH1A1 P00352 2/20 0.57
TSHR P16473 1/20 0.55
PDE1A P54750 1/20 0.54
PDE1B Q01064 1/20 0.54
PDE1C Q14123 1/20 0.54
ALOX15 P16050 1/20 0.54
HSD17B10 Q99714 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
GAA P10253 1/20 0.53
GLA P06280 1/20 0.53
HTT P42858 1/20 0.53
UBE2N P61088 1/20 0.53
HTR7 P34969 1/20 0.52
HTR6 P50406 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683975 0.91 LMNA (0.65) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL684003 0.91 SMN1; SMN2 (0.68) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL682800 0.90 RXFP1 (0.63) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL683588 0.88 ALDH1A1 (0.57) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL682806 0.88 LMNA (0.62) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL684337 0.88 SMN1; SMN2 (0.68) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL684336 0.87 RXFP1 (0.54) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL683977 0.87 SMN1; SMN2 (0.61) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL683589 0.86 ALDH1A1 (0.54) SMN1; SMN2RXFP1ADORA2BLMNAPOLB
SCHEMBL683590 0.85 SMN1; SMN2 (0.64) SMN1; SMN2RXFP1LMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF SMN1; SMN2 907/4885RXFP1 211/4885ADORA2B 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.